Friday, Nov. 6, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $473.82 to $10,527,076.00.

Highlighted Stocks Traded by Insiders:

MaxLinear (MXL) - FREE Research Report

Moyer Albert J, who is Director at MaxLinear, sold 11,544 shares at $16.50 on Nov. 6, 2015. Following this transaction, the Director owned 54,708 shares meaning that the stake was reduced by 17.42% with the 11,544-share transaction.

The shares most recently traded at $17.09, up $0.59, or 3.45% since the insider transaction. Historical insider transactions for MaxLinear go as follows:

  • 4-Week # shares sold: 4,597
  • 12-Week # shares sold: 4,597
  • 24-Week # shares sold: 25,000

The average volume for MaxLinear has been 889,300 shares per day over the past 30 days. MaxLinear has a market cap of $883.6 million and is part of the technology sector and electronics industry. Shares are up 134.28% year-to-date as of the close of trading on Friday.

MaxLinear, Inc. provides integrated, radio-frequency (RF) and mixed-signal circuits for broadband communication and data center, metro, and long-haul transport network applications worldwide. Currently, there are 6 analysts who rate MaxLinear a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MXL - FREE

TheStreet Quant Ratings

rates MaxLinear as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

MaxLinear Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

comScore (SCOR) - FREE Research Report

Lin Christiana L, who is General Counsel at comScore, sold 1,000 shares at $44.81 on Nov. 6, 2015. Following this transaction, the General Counsel owned 64,072 shares meaning that the stake was reduced by 1.54% with the 1,000-share transaction.

The shares most recently traded at $45.20, up $0.39, or 0.86% since the insider transaction. Historical insider transactions for comScore go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 73,037
  • 24-Week # shares sold: 155,639

The average volume for comScore has been 495,800 shares per day over the past 30 days. comScore has a market cap of $1.8 billion and is part of the services sector and diversified services industry. Shares are up 0.3% year-to-date as of the close of trading on Friday.

comScore, Inc. provides digital media analytics products and services for content publishers, advertisers, advertising agencies, and network operators primarily in the United States, Canada, Europe, Latin America, and Asia. Currently, there are 5 analysts who rate comScore a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCOR - FREE

TheStreet Quant Ratings

rates comScore as a

hold

. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full

comScore Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Supernus Pharmaceuticals (SUPN) - FREE Research Report

Bhatt Padmanabh P., who is Sr. VP of IP, CSO at Supernus Pharmaceuticals, sold 5,000 shares at $19.90 on Nov. 6, 2015. Following this transaction, the Sr. VP of IP, CSO owned 102,306 shares meaning that the stake was reduced by 4.66% with the 5,000-share transaction.

The shares most recently traded at $18.51, down $1.39, or 7.51% since the insider transaction. Historical insider transactions for Supernus Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,350
  • 12-Week # shares sold: 2,350
  • 24-Week # shares sold: 16,199

The average volume for Supernus Pharmaceuticals has been 840,700 shares per day over the past 30 days. Supernus Pharmaceuticals has a market cap of $861.4 million and is part of the health care sector and drugs industry. Shares are up 118.19% year-to-date as of the close of trading on Friday.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has a P/E ratio of 52.3. Currently, there are 6 analysts who rate Supernus Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SUPN - FREE

TheStreet Quant Ratings

rates Supernus Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full

Supernus Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.